Haemonetics Corporation
HAE · NYSE
3/29/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.44 | 16.60 | 0.22 | -1.62 |
| FCF Yield | 4.48% | 2.69% | 3.88% | 2.35% |
| EV / EBITDA | 12.15 | 18.56 | 18.78 | 20.96 |
| Quality | ||||
| ROIC | 8.06% | 6.70% | 7.51% | 3.36% |
| Gross Margin | 55.04% | 52.83% | 52.63% | 50.90% |
| Cash Conversion Ratio | 1.08 | 1.55 | 2.37 | 3.97 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.21% | 9.64% | 10.32% | 0.16% |
| Free Cash Flow Growth | 23.38% | -29.11% | 114.99% | 5.56% |
| Safety | ||||
| Net Debt / EBITDA | 2.72 | 2.37 | 1.93 | 2.88 |
| Interest Coverage | 22.76 | 12.67 | 10.67 | 4.72 |
| Efficiency | ||||
| Inventory Turnover | 1.68 | 1.95 | 2.13 | 1.66 |
| Cash Conversion Cycle | 232.21 | 201.73 | 184.82 | 234.19 |